Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Coronavirus disease 2019 (COVID-19) has caused an enormous loss of life worldwide. The spike protein of the severe acute respiratory syndrome coronavirus 2 is the cause of its virulence. Bamlanivimab, a recombinant monoclonal antibody, has been used alone or in combination with etesevimab to provide passive immunity and improve clinical outcomes. A systematic review and meta-analysis was conducted to investigate the therapeutic effects of bamlanivimab with or without etesevimab (BAM/ETE) treatment.
Methods: Our study was registered in PROSPERO (registry number CRD42021270206). We searched the following electronic databases, without language restrictions, until January 2023: PubMed, Embase, medRxiv, and the Cochrane database. A systematic review and meta-analysis was conducted based on the search results.
Results: Eighteen publications with a total of 28,577 patients were identified. Non-hospitalized patients given bamlanivimab with or without etesevimab had a significantly lower risk of subsequent hospitalization (18 trials, odds ratio (OR): 0.37, 95% confidence interval (CI): [0.29-0.49], : 69%; < 0.01) and mortality (15 trials, OR: 0.27, 95% CI [0.17-0.43], : 0%; = 0.85). Bamlanivimab monotherapy also reduced the subsequent risk of hospitalization (16 trials, OR: 0.43, 95% CI [0.34-0.54], : 57%; = 0.01) and mortality (14 trials, OR: 0.28, 95% CI [0.17-0.46], : 0%; = 0.9). Adverse events from these medications were uncommon and tolerable.
Conclusions: In this meta-analysis, we found the use of bamlanivimab with or without etesevimab contributed to a significantly-reduced risk of subsequent hospitalization and mortality in non-hospitalized COVID-19 patients. However, resistance to monoclonal antibodies was observed in COVID-19 variants, resulting in the halting of the clinical use of BAM/ETE. Clinicians' experiences with BAM/ETE indicate the importance of genomic surveillance. BAM/ETE may be repurposed as a potential component of a cocktail regimen in treating future COVID variants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174063 | PMC |
| http://dx.doi.org/10.7717/peerj.15344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A comprehensive panel of testing for amyloidosis.
J Histotechnol
September 2025
Department of Pathology, Peking University Third Hospital, Beijing, China.
Amyloidosis encompasses a spectrum of rare disorders characterized by extracellular amyloid deposition. Achieving an accurate early diagnosis of systemic amyloidosis necessitates biopsy-specific pathological evaluation. Formalin-fixed, paraffin-embedded liver biopsy specimens were examined using Congo red staining, electron microscopy, immunohistochemistry (IHC), immunofluorescence, and Congo red-assisted laser microdissection with mass spectrometry (LMD/MS).
View Article and Find Full Text PDFGenetic factors associated with the co-occurrence of endometriosis with antiphospholipid syndrome (Review).
Exp Ther Med
October 2025
Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, 71003 Heraklion, Greece.
Immune-related factors may serve an important role in the development of endometriosis, considering the occurrence of substantial abnormalities in the immune system of women with endometriosis, including reduced T-cell reactivity and natural killer cell cytotoxicity, as well as increased numbers and activation of peritoneal macrophages. Moreover, women suffering from endometriosis are at a higher risk for developing various autoimmune diseases as comorbidities of endometriosis. Recent epidemiological data demonstrate that patients with endometriosis have a significantly higher risk (2.
View Article and Find Full Text PDFUltra-sensitive pH responsive hydrogels with injectable and self-healing performance for controlled drug delivery.
Int J Pharm X
June 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
Ultra-sensitive pH-responsive drug delivery system designed to operate within the slightly acidic microenvironment of tumors are highly desired for hydrogel applications in cancer therapy. In this study, 4-Formylbenzoic acid modified polyvinyl alcohol (PVA-FBA, PF) was synthesized and utilized as a carrier for encapsulating the anticancer drug Doxorubicin (Dox). This was subsequently crosslinked with polyethylenimine (PEI) via benzoic-imine bond to form drug-loaded PVA-FBA/PEI hydrogel (D-PFP).
View Article and Find Full Text PDFReducing motion artifacts in craniocervical background subtraction angiography with deformable registration and unsupervised deep learning.
Radiol Adv
September 2024
Department of Radiology, Northwestern University and Northwestern Medicine, Chicago, IL, 60611, United States.
Background: In clinical practice, digital subtraction angiography (DSA) often suffers from misregistration artifact resulting from voluntary, respiratory, and cardiac motion during acquisition. Most prior efforts to register the background DSA mask to subsequent postcontrast images rely on key point registration using iterative optimization, which has limited real-time application.
Purpose: Leveraging state-of-the-art, unsupervised deep learning, we aim to develop a fast, deformable registration model to substantially reduce DSA misregistration in craniocervical angiography without compromising spatial resolution or introducing new artifacts.
Refractory extra nodal follicular dendritic cell sarcoma in a young male exhibiting a marked response to gemcitabine and docetaxel: A case report and literature review.
Med Int (Lond)
August 2025
Department of Oncology, Combined Military Hospital/National University of Medical Sciences, Rawalpindi 46000, Pakistan.
Follicular dendritic cell sarcoma (FDCS) is a rare tumour derived from dendritic cells located in B-follicles that play a pivotal role in the adaptive immune response. Surgery is the mainstay of treatment for localized disease; however, the management of unresectable or advanced disease is less well-defined. To date, to the best of our knowledge, there is no established or preferred chemotherapeutic regimen, although a number of regimens (primarily used in lymphomas and sarcomas) have been utilized with suboptimal outcomes.
View Article and Find Full Text PDF